EXEL
Exelixis Inc
NASDAQ: EXEL · HEALTHCARE · BIOTECHNOLOGY
$44.69
-0.53% today
Updated 2026-04-29
Market cap
$11.35B
P/E ratio
16.08
P/S ratio
4.89x
EPS (TTM)
$2.78
Dividend yield
—
52W range
$34 – $50
Volume
2.7M
Exelixis Inc (EXEL) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$44.69
12-Month target
$41.91
2030 Target
—
Intrinsic (DCF)
$165.35
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.6B | $1.8B | $2.2B | $2.3B | $2.8B | $3.3B | $3.9B | $4.6B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 18.63% (capped 20%) · P/E: 16.08x (capped 25x) · Margin: 33.70%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.